Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study

Dalia Omran1*, Mohamed Al Soda2, Eshak Bahbah3, Gamal Esmat1, Hend Shousha1, Ahmed Elgebaly4, Muhammad Abdel Ghaffar5, Mohamed Alsheikh6, Enass El Sayed7, Shimaa Afify8, Samah Abdel Hafez2, Khaled Elkellany9, Ayman Eltayar10, Omnia Ali11, Lamiaa Kamal12, Ahmed Heiba5,13

1 Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt, 2 General Organization for Teaching Hospitals and Institutes, Cairo, Egypt, 3 Faculty of Medicine, Al-Azhar University, Damietta, Egypt, 4 Faculty of Medicine, Al-Azhar University, Cairo, Egypt, 5 Gastroenterology & Infectious Diseases Department, Ahmed Maher Teaching Hospital, Cairo, Egypt, 6 Chest Unit, Al Matareyyah Teaching Hospital, Cairo, Egypt, 7 Nephrology Department, Ahmed Maher Teaching Hospital, Cairo, Egypt, 8 Gastroenterology Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt, 9 Pediatric Department, Shebin Elkom Teaching Hospital, Shebin Elkom, Egypt, 10 Intensive care Department, Damanhour Teaching Hospital, Damanhour, Egypt, 11 Clinical and Chemical Pathology Department, Ahmed Maher Teaching Hospital, Cairo, Egypt, 12 Clinical and Chemical Pathology Department, Elsahel Teaching Hospital, Cairo, Egypt, 13 Internal Medicine Department, National Research Centre, Cairo, Egypt

* daliaomran@kasralainy.edu.eg

Abstract

Objectives

We conducted the present multicenter, retrospective study to assess the epidemiological, clinical, laboratory, and radiological characteristics associated with critical illness among patients with COVID-19 from Egypt.

Methods

The present study was a multicenter, retrospective study that retrieved the data of all Egyptian cases with confirmed COVID-19 admitted to hospitals affiliated to the General Organization for Teaching Hospitals and Institutes (GOTHI) through the period from March to July 2020. The diagnosis of COVID-19 was based on a positive reverse transcription-polymerase chain reaction (RT-PCR) laboratory test.

Results

This retrospective study included 2724 COVID-19 patients, of whom 423 (15.52%) were critically ill. Approximately 45.86% of the critical group aged above 60 years, compared to 39.59% in the non-critical group (p = 0.016). Multivariable analysis showed that many factors were predictors of critically illness, including age >60 years (OR = 1.30, 95% CI [1.05, 1.61], p = 0.014), low oxygen saturation (OR = 0.93, 95% CI [0.91, 0.95], p<0.001), low Glasgow coma scale (OR = 0.75, 95% CI [0.67, 0.84], p<0.001), diabetes (OR = 1.62, 95% CI [1.26,
Conclusion
In the present report, we demonstrated that many factors are associated with COVID-19 critical illness, including older age groups, fatigue, elevated temperature, increased pulse, lower oxygen saturation, the preexistence of diabetes, malignancies, cardiovascular disease, renal diseases, and pulmonary disease. Moreover, elevated serum levels of ALT, AST, and ferritin are associated with worse outcomes. Further studies are required to identify independent predictors of mortality for patients with COVID-19.

1. Introduction
Since the discovery of the initial cluster of cases in Wuhan, China, the coronavirus disease 2019 (COVID-19) outbreak has emerged as one the greatest health threats and was declared as a pandemic by the World Health Organization (WHO) on March 11, 2020 [1, 2]. By the end of October 2020, the COVID-19 outbreak has affected more than 200 countries in various regions of the world; according to the WHO situation reports, the number of COVID-19 confirmed cases reached more than 41,571,000 cases and 1,135,000 related deaths worldwide [3]. In the past few months, the COVID-19 pandemic landscape has changed with a dramatic shift in the apex of the number of confirmed cases from China to the United States (US), Europe, and Eastern Mediterranean Region (EMR) [4, 5]. In the EMR, the number of confirmed cases is approaching three million cases by October 2020, with a fatality rate of 2.6% [6]. While the causative agents and mode of transmission remained ambiguous during the early day of outbreaks, it is now clear that COVID-19 is a highly contagious disease that is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted mainly by respiratory droplets [7, 8]. Besides, the current body of evidence demonstrates that the infection can be transmitted by both symptomatic and asymptomatic cases leading to the dramatic spread of the outbreak within the community [9].

The presentation and outcomes of COVID-19 vary substantially, with clinical features ranging from asymptomatic/mild symptoms to fatal respiratory distress and multi-organ failure [10, 11]. Previous reports demonstrated that symptomatic patients usually present with flu-like symptoms that resolve completely by the end of the disease course [12]; nonetheless, a subset of the patients can present with severe forms of the disease, including severe pneumonia, acute respiratory distress syndrome (ARDS), sepsis, thromboembolic manifestations, acute myocarditis, septic shock, multi-organ failure, and eventually death [13–16]. While the exact pathogenic mechanisms underlying the development of severe forms have not been fully elucidated yet, recent experiments highlighted that patients with severe COVID-19 exhibit exaggerated inflammatory process and release of inflammatory cytokines, which in rerun induce a cytokine storm and organ damage [17].

Recent studies confirmed that the COVID-19 outbreak does not exert an equal toll amongst the different regions affected, with wide variation in the proportion of patients with severe disease and mortality [18]. While the adequacy of healthcare services may play a role in such inconsistencies [19], multicenter reports highlighted that patient-specific factors are major determinants of the presentation and outcomes of COVID-19. Old age, male gender, comorbidities, and immunocompromised status were reported to be associated with severe
presentation and poor disease outcomes [20, 21]; besides, predisposing genetic factors may play a role in determining an individual’s susceptibility to infection and disease course as well [22, 23].

Being a frequent destination of tourism, international traffic and a densely populated country, Egypt observed an increasing spread of COVID-19 since March 5; the official figures demonstrated the number of confirmed cases was nearly 108,000 by the end of October 2020 with a fatality rate of 5.8% [24]. Besides, the mortality rate among hospitalized patients with COVID-19 in Egypt was reported to be 6.7% [25], which rises to 40% in severe and critically-ill cases [26]. Such a fatality rate is notably higher than in other countries in the EMR, which can be attributed to the potential role of patient-specific characteristics. Thus, we conducted the present retrospective study to assess the epidemiological, clinical, laboratory, and radiological characteristics associated with critical illness development among patients with COVID-19 from Egypt.

2. Materials and methods

The present study was initiated after obtaining the protocol approval from the General Organization for Teaching Hospitals and Institutes (GOTHI) responsible ethics committees in Egypt (IRB:HAM00122). The preparation of the present manuscript runs in compliance with the recommendations of the STROBE statement [27].

2.1. Study design and population

The present study was a multicenter, retrospective study that retrieved the data of all Egyptian cases with confirmed COVID-19 admitted to hospitals affiliated to the GOTHI through the period from March to July 2020. The diagnosis of COVID-19 was based on a positive reverse transcription-polymerase chain reaction (RT-PCR) laboratory test.

2.2. Data collection and operational definitions

We retrieved epidemiological, clinical, laboratory, and radiological data of all eligible patients. The epidemiological characteristics included age, gender, and smoking, while the clinical data included the COVID-19 symptoms and the associated comorbidities. The laboratory and radiological data included complete blood count (CBC) with differential count, C-reactive protein (CRP), serum ferritin, liver function tests, renal function tests, coagulation profile, D-Dimer level, arterial blood gas analysis, and chest imaging. The data were collected at the first day of hospitalization of each patient.

According to Chinese guidelines for the management of COVID-19; Severe COVID-19 was defined as the presence of radiological evidence of more than 50% lung infiltrate plus one of the following: respiratory rate of \( \geq 30 \) breaths per minute; oxygen saturation (SpO2) <94% while breathing ambient air at rest; or ARDS that is defined as arterial oxygen partial pressure (PaO2) to a fraction of inspired oxygen (FiO2) (PaO2: FiO2) of \( \leq 300 \) mmHg. In addition, critical COVID-19 was defined as respiratory failure requiring ventilator support either invasive or non invasive, septic shock, and/or any organ dysfunction that needs supportive treatment in ICU [28].

2.3. Statistical analysis

Data were analyzed using the software Stata 16 for Windows. Categorical variables were summarized by frequency counts and percentages. Continuous variables were represented as means and standard deviations. Comparison between moderate and severe cases to critically-
ill cases was done through univariate analysis as follows: categorical variables were assessed with the Chi-square test, whereas continuous variables were assessed using the Mann-Whitney test. Multivariate analysis was also done to determine factors associated with patients’ deterioration. The odds ratio (OR) was calculated by using stepwise logistic regression modeling. Accordingly, the regression equation was used to calculate predicted probabilities of patients’ deterioration. Multivariate regression was validated using the Hosmer-Lemeshow goodness-of-fit test.

3. Results

3.1. Demographic characteristics

This retrospective study included 2724 COVID-19 patients, of whom 423 (15.52%) were critically ill. Approximately 45.86% of the critical group aged above 60 years, compared to 39.59% in the non-critical group (p = 0.016). There was no significant difference between both groups in terms of gender (p = 0.655) and smoking (p = 0.218), Table 1.

3.2. COVID-19 symptoms

Regarding the history of contact with infected persons, 25.06% of the critical group’s patients had a contact history, compared to 18.47% in the non-critical group (p = 0.002). Our analysis demonstrated no significant difference between both groups in regards to the presence of fever (p = 0.163), cough (p = 0.212), dyspnea (p = 0.390), sore throat (p = 0.283), hemoptysis (p = 0.055), headache (p = 0.298), diarrhea (p = 0.171), nausea (p = 0.703), vomiting (p = 0.646), abdominal pain (p = 0.972), loss of taste (p = 0.151), and loss of smell (p = 0.239). On the other hand, prevalence of fatigue (32.15% vs. 23.73%, p < 0.001), anorexia (5.44% vs. 2.96%, p = 0.009), arthralgia (13.71% vs. 6.48%, p < 0.001), and myalgia (16.31% vs. 8.52%, p < 0.001) was significantly higher in the critical group compared with non-critical group, respectively (Table 1).

3.3. Co-morbidities

Patients with critical illness were associated with higher prevalence of diabetes (39.72% vs. 27.86%, p < 0.001), cancer (4.49% vs. 1.91%, p = 0.001), hypertension (33.57% vs. 27.03%, p = 0.006), coronary artery diseases (12.53% vs. 6.95%, p < 0.001), chronic renal insufficiency (7.09 vs. 2.74%, p < 0.001), and asthma (1.42% vs. 0.78%, p = 0.006), Table 1.

3.4. CT findings

Interestingly, there was no significant difference (p = 0.566) between critical and non-critical groups in terms of CT findings, including consolidation (3.07% vs. 2.39%), Crazy paving (1.18% vs. 1%), and Ground Glass Opacity (39.95% vs. 44.89%), Table 1.

3.5. Vital signs and O₂ saturation

There was no significant difference between both groups in terms of systolic and diastolic blood pressure (p = 0.762 and p = 0.577, respectively). On the other hand, the mean value of the pulse (p = 0.006), temperature (p<0.001), and respiratory rate (p<0.001) was higher in critically ill patients compared to the non-critical group. Moreover, the FiO2 was significantly (p = 0.004) higher in the critical group (35.5±33.9) compared to the non-critical group (20.71±28.08). In terms of oxygen saturation, critically ill patients were associated with lower O2 saturation (85.73±10.6 vs. 91.04±6.23, p<0.001) and partial pressure of O2 (64.43±26.09 vs 55.22
Table 1. Demographic, clinical, and radiological characteristics of included patients.

| Parameters                  | Total (n = 2724) | Non-critically COVID-19 (n = 2301) | Critically COVID-19 (n = 423) | P-value |
|-----------------------------|------------------|-----------------------------------|-------------------------------|---------|
| **Age group**               |                  |                                   |                               |         |
| 0–9                         | 14 (0.51%)       | 12 (0.47%)                        | 2 (0.47%)                     | P = 0.119 |
| 10–19                       | 17 (0.62%)       | 16 (0.70%)                        | 1 (0.24%)                     |         |
| 20–29                       | 108 (3.96%)      | 94 (4.09%)                        | 14 (3.31%)                    |         |
| 30–39                       | 291 (10.68%)     | 263 (11.43%)                      | 28 (6.62%)                    |         |
| 40–49                       | 519 (19.05%)     | 444 (19.30%)                      | 75 (17.73%)                   |         |
| 50–59                       | 670 (24.60%)     | 561 (24.38%)                      | 109 (25.77%)                  |         |
| 60–69                       | 629 (23.09%)     | 512 (22.25%)                      | 117 (27.66%)                  |         |
| 70–79                       | 385 (14.13%)     | 323 (14.04%)                      | 62 (14.66%)                   |         |
| 80–89                       | 86 (3.16%)       | 72 (3.13%)                        | 14 (3.31%)                    |         |
| 90–99                       | 4 (0.15%)        | 3 (0.13%)                         | 1 (0.24%)                     |         |
| ≥100                        | 1 (0.04%)        | 1 (0.04%)                         | 0 (0.00%)                     |         |
| **Age > 60 years**          |                  |                                   |                               |         |
| No                          | 1619 (59.43%)    | 1390 (59.41%)                     | 229 (54.14%)                  | P = 0.016 |
| Yes                         | 1105 (40.57%)    | 911 (40.59%)                      | 219 (45.86%)                  |         |
| **Gender**                  |                  |                                   |                               |         |
| Male                        | 1396 (51.25%)    | 1175 (51.06%)                     | 221 (52.25%)                  | 0.655   |
| Female                      | 1328 (48.75%)    | 1126 (48.94%)                     | 202 (47.75%)                  |         |
| **Smoking**                 |                  |                                   |                               |         |
| No                          | 2387 (87.63%)    | 2024 (87.96%)                     | 363 (85.82%)                  | 0.218   |
| Yes                         | 287 (10.54%)     | 227 (9.87%)                       | 60 (14.18%)                   |         |
| **Contact History**         |                  |                                   |                               |         |
| No                          | 2193 (80.51%)    | 1876 (81.53%)                     | 317 (74.94%)                  | 0.002   |
| Yes                         | 531 (19.49%)     | 425 (18.47%)                      | 106 (25.06%)                  |         |
| **Asymptomatic**            |                  |                                   |                               |         |
| No                          | 2474 (90.82%)    | 2091 (90.87%)                     | 383 (90.54%)                  | 0.829   |
| Yes                         | 250 (9.18%)      | 210 (9.13%)                       | 40 (9.46%)                    |         |
| **Fever**                   |                  |                                   |                               |         |
| No                          | 792 (29.07%)     | 681 (29.60%)                      | 111 (26.24%)                  | 0.163   |
| Yes                         | 1932 (70.93%)    | 1620 (70.40%)                     | 312 (73.76%)                  |         |
| **Cough**                   |                  |                                   |                               |         |
| No                          | 1118 (41.04%)    | 956 (41.55%)                      | 162 (38.30%)                  | 0.212   |
| Yes                         | 1606 (58.96%)    | 1345 (58.45%)                     | 261 (61.70%)                  |         |
| **Dyspnea**                 |                  |                                   |                               |         |
| No                          | 834 (30.62%)     | 697 (30.29%)                      | 137 (32.30%)                  | 0.390   |
| Yes                         | 1890 (69.38%)    | 1604 (69.71%)                     | 286 (67.61%)                  |         |
| **Sore throat**             |                  |                                   |                               |         |
| No                          | 1927 (70.74%)    | 1637 (71.14%)                     | 290 (68.56%)                  | 0.283   |
| Yes                         | 797 (29.26%)     | 664 (28.86%)                      | 133 (31.44%)                  |         |
| **Hemoptysis**              |                  |                                   |                               |         |
| No                          | 2714 (99.63%)    | 2295 (99.74%)                     | 419 (99.05%)                  | 0.055   |
| Yes                         | 10 (0.37%)       | 6 (0.26%)                         | 4 (0.95%)                     |         |
| **Headache**                |                  |                                   |                               |         |
| No                          | 2717 (99.74%)    | 2296 (99.78%)                     | 421 (99.53%)                  | 0.298   |
| Yes                         | 7 (0.26%)        | 5 (0.22%)                         | 2 (0.47%)                     |         |
| **Fatigue**                 |                  |                                   |                               | <0.001  |
| No                          | 2042 (74.96%)    | 1755 (76.27%)                     | 287 (67.85%)                  |         |
| Yes                         | 688 (25.04%)     | 546 (23.73%)                      | 136 (32.15%)                  |         |
| **Anorexia**                |                  |                                   |                               | 0.009   |
| No                          | 2633 (96.66%)    | 2233 (97.04%)                     | 400 (94.56%)                  |         |
| Yes                         | 91 (3.34%)       | 68 (2.96%)                        | 23 (5.44%)                    |         |
| **Diarrhea**                |                  |                                   |                               | 0.171   |
| No                          | 2552 (93.69%)    | 2162 (93.96%)                     | 390 (92.20%)                  |         |
| Yes                         | 172 (6.31%)      | 139 (6.04%)                       | 33 (7.80%)                    |         |
| **Nausea**                  |                  |                                   |                               | 0.703   |
| No                          | 2565 (94.16%)    | 2165 (94.09%)                     | 400 (94.56%)                  |         |
| Yes                         | 159 (5.84%)      | 136 (5.91%)                       | 23 (5.44%)                    |         |
| **Vomiting**                |                  |                                   |                               | 0.646   |
| No                          | 2556 (93.83%)    | 2157 (93.74%)                     | 399 (94.33%)                  |         |
| Yes                         | 168 (6.17%)      | 144 (6.26%)                       | 24 (5.67%)                    |         |
| **Abdominal pain**          |                  |                                   |                               | 0.972   |
| No                          | 2646 (97.14%)    | 2235 (97.13%)                     | 411 (97.16%)                  |         |
| Yes                         | 78 (2.86%)       | 66 (2.87%)                        | 12 (2.84%)                    |         |

(Continued)
The Glasgow coma scale was significantly (p < 0.001) lower in the critical group (14.10 ± 2.33) than the non-critical group (14.80 ± 0.78), Table 2.

### 3.6. Laboratory investigations

Critically ill patients were associated with higher serum levels of CRP (p < 0.001), Serum ferritin (p = 0.003), TLC (p < 0.001), INR (p < 0.001), serum potassium (p = 0.023), HCO3 (p = 0.029), and Moreover, total bilirubin (p < 0.001), direct bilirubin (p < 0.001), serum albumin (p = 0.001), ALT (p = 0.008), AST (p < 0.001), and serum creatinine (p = 0.007) were higher in critically ill patients, Table 2.

| Parameters                  | Total   | Non-critically COVID-19 | Critically COVID-19 | P-value |
|-----------------------------|---------|-------------------------|---------------------|---------|
| Arthralgia                  |         |                         |                     |         |
| No                          | 2517 (92.40%) | 2152 (93.52%)          | 365 (86.29%)       | <0.001  |
| Yes                         | 207 (7.60%)  | 149 (6.48%)            | 58 (13.71%)        |         |
| Myalgia                     |         |                         |                     |         |
| No                          | 2459 (90.27%) | 2105 (91.48%)          | 354 (83.69%)       | <0.001  |
| Yes                         | 265 (9.73%)  | 196 (8.52%)            | 69 (16.31%)        |         |
| Loss of taste               |         |                         |                     |         |
| No                          | 2597 (95.34%) | 2188 (95.09%)          | 409 (96.69%)       | 0.151   |
| Yes                         | 127 (4.66%)  | 113 (4.91%)            | 14 (3.31%)         |         |
| Loss of smell               |         |                         |                     |         |
| No                          | 2634 (96.70%) | 2221 (96.52%)          | 413 (97.64%)       | 0.239   |
| Yes                         | 92 (3.38%)   | 82 (3.56%)             | 10 (2.36%)         |         |
| Number of symptoms          |         |                         |                     |         |
| <7                          | 26 (0.95%)   | 21 (0.91%)             | 5 (1.18%)          | 0.586   |
| ≥7                          | 2698 (99.05%) | 2280 (99.09%)          | 418 (98.82%)       |         |
| Diabetes                    |         |                         |                     |         |
| No                          | 1915 (70.30%) | 1660 (72.14%)          | 255 (60.28%)       | <0.001  |
| Yes                         | 809 (29.70%) | 641 (27.86%)           | 168 (39.72%)       |         |
| Cancer                      |         |                         |                     |         |
| No                          | 2661 (97.69%) | 2257 (98.09%)          | 404 (95.51%)       | 0.001   |
| Yes                         | 63 (2.31%)   | 44 (1.91%)             | 19 (4.49%)         |         |
| Hypertension                |         |                         |                     |         |
| No                          | 1960 (71.95%) | 1679 (72.97%)          | 281 (66.43%)       | 0.006   |
| Yes                         | 764 (28.05%) | 622 (27.03%)           | 142 (33.57%)       |         |
| Chronic liver disease       |         |                         |                     |         |
| No                          | 2616 (96.04%) | 2214 (96.22%)          | 402 (95.04%)       | 0.252   |
| Yes                         | 108 (3.96%)  | 87 (3.78%)             | 21 (4.96%)         |         |
| Liver Cirrhosis             |         |                         |                     |         |
| No                          | 2652 (97.36%) | 2246 (97.61%)          | 406 (95.98%)       | 0.055   |
| Yes                         | 72 (2.64%)   | 55 (2.39%)             | 17 (4.02%)         |         |
| Asthma                      |         |                         |                     |         |
| No                          | 24 (0.88%)   | 18 (0.78%)             | 6 (1.42%)          |         |
| Yes                         | 2700 (99.12%) | 2283 (99.22%)          | 417 (98.58%)       |         |
| Coronary artery disease     |         |                         |                     |         |
| No                          | 2511 (92.18%) | 2141 (93.05%)          | 370 (87.47%)       | <0.001  |
| Yes                         | 213 (7.82%)  | 160 (6.95%)            | 53 (12.53%)        |         |
| Chronic Renal Insufficiency |         |                         |                     |         |
| No                          | 2631 (96.59%) | 2238 (97.26%)          | 393 (92.91%)       | <0.001  |
| Yes                         | 93 (3.41%)   | 63 (2.74%)             | 30 (7.09%)         |         |
| Heart Failure               |         |                         |                     |         |
| No                          | 2720 (99.85%) | 2297 (99.83%)          | 423 (100.00%)      | 1.00    |
| Yes                         | 4 (0.15%)    | 4 (0.17%)              | 0 (0.00%)          |         |
| Dyslipidemia                |         |                         |                     |         |
| No                          | 2721 (99.89%) | 2298 (99.87%)          | 423 (100.00%)      | 0.457   |
| Yes                         | 3 (0.11%)    | 3 (0.13%)              | 0 (0.00%)          |         |
| CT findings                 |         |                         |                     |         |
| Normal                      | 8 (0.29%)    | 8 (0.35%)              | 0 (0.00%)          | 0.566   |
| Consolidation               | 68 (2.50%)   | 55 (2.39%)             | 13 (3.07%)         |         |
| Crazy paving                | 28 (1.03%)   | 23 (1.00%)             | 5 (1.18%)          |         |
| Ground Glass opacity        | 1202 (44.13%) | 1033 (44.89%)          | 169 (39.95%)       |         |
| Others not related to COVID-19 | 2 (0.07%)  | 2 (0.09%)              | (0.00%)            |         |

https://doi.org/10.1371/journal.pone.0256203.t001
3.7. Univariate logistic regression

Our analysis demonstrated a significant association between many variables and critical illness. In terms of demographic variables age >60 years and history of contact were observed to increase the risk of critically illness (OR = 1.29, 95% CI [1.04, 1.59], p = 0.016) and (OR = 1.47, 95% CI [1.15, 1.88], p = 0.002), respectively. Regarding the COVID-19 symptoms, critically illness was significantly associated with hemoptysis (OR = 3.65, 95% CI [1.02, 12.99], p = 0.046), fatigue (OR = 1.52, 95% CI [1.21, 1.91], p < 0.001), anorexia (OR = 1.88, 95% CI [1.16, 3.06], p = 0.010), arthralgia (OR = 2.29, 95% CI [1.66, 3.17], p < 0.001), and myalgia (OR = 2.09, 95% CI [1.55, 2.82], p < 0.001). In terms of co-morbidities, patients with diabetes (OR = 1.71, 95% CI [1.38, 2.12], p < 0.001), cancer (OR = 2.41, 95% CI [1.39, 4.17], p = 0.002), hypertension (OR = 1.36, 95% CI [1.09, 1.70], p = 0.006), and coronary artery diseases (OR = 1.91, 95% CI [1.37, 2.66], p < 0.001) were associated with higher risk of critical illness, Table 3.
3.8. Predictors of critical illness

Multivariate analysis was performed based on four models; 1) demographic and clinical symptoms; 2) vital signs; 3) Co-morbidities; and 4) laboratory investigations. Model 1 showed that age > 60 years (OR = 1.30, 95% CI [1.05, 1.61], p = 0.014), fatigue (OR = 1.52, 95% CI [1.21, 1.91], p < 0.001), arthralgia (OR = 1.75, 95% CI [1.20, 2.54], p = 0.003), and myalgia (OR = 1.51, 95% CI [1.08, 2.11], p = 0.015) can be considered as independent predictors for COVID-19 critical illness. Model 2 demonstrated that high pulse (OR = 1.01, 95% CI [1.009, 1.03], p < 0.001), temperature (OR = 1.25, 95% CI [1.04, 1.48], p = 0.012), low oxygen saturation (OR = 0.93, 95% CI [0.91, 0.95], p < 0.001), and low Glasgow coma scale (OR = 0.75, 95% CI [0.67, 0.84], p < 0.001) are significant predictors for COVID-19 critical illness. According to
model 3, critical COVID-19 can be predicted based on the presence of the following co-morbidities: Diabetes (OR = 1.62, 95% CI [1.26, 2.08], p<0.001), cancer (OR = 2.47, 95% CI [1.41, 4.35], p = 0.002), coronary artery diseases (OR = 1.56, 95% CI [1.09, 2.22], p = 0.014), and chronic renal insufficiency (OR = 2.81, 95% CI [1.79, 4.43], p<0.001). Regarding model 4, only ALT (OR = 1.12, 95% CI [1.0092, 1.24], p = 0.033), AST (OR = 1.13, 95% CI [1.00, 1.28], p = 0.036), and Serum ferritin (OR = 1.004, 95% CI [1.0003, 1.008], p = 0.031) can be used as predictors for COVID-19 critical illness, Table 4.

Table 4. Multivariate analysis of risk factors.

| Models          | Multivariate analysis | P-value | Hosmer-Lemeshow goodness-of-fit test | Chi² p-value |
|-----------------|-----------------------|---------|--------------------------------------|-------------|
| Model 1*        | Age >60 years          | 1.30 (1.05, 1.61) | 0.014 | 2.98 | 0.5618 |
|                 | History of contact     | 1.20 (0.93, 1.56) | 0.151 |       |       |
|                 | Hemoptysis             | 3.14 (0.82, 11.98) | 0.094 |       |       |
|                 | Fatigue                | 1.30 (1.02, 1.65) | 0.029 |       |       |
|                 | Anorexia               | 1.04 (0.60, 1.78) | 0.886 |       |       |
|                 | Arthralgia             | 1.75 (1.20, 2.54) | 0.003 |       |       |
|                 | Myalgia                | 1.51 (1.08, 2.11) | 0.015 |       |       |
| Model 2**       | Pulse                  | 1.01 (1.009, 1.03) | <0.001 | 21.38 | 0.0062 |
|                 | Temperature            | 1.25 (1.04, 1.48) | 0.012 |       |       |
|                 | Respiratory rate       | 1.01 (0.99, 1.03) | 0.181 |       |       |
|                 | Oxygen Saturation      | 0.93 (0.91, 0.95) | <0.001 |       |       |
|                 | Glasgow coma scale     | 0.75 (0.67, 0.84) | <0.001 |       |       |
| Model 3***      | Diabetes               | 1.62 (1.26, 2.08) | <0.001 |       |       |
|                 | Cancer                 | 2.47 (1.41, 4.35) | 0.002 |       |       |
|                 | Hypertension           | 0.93 (0.71, 1.22) | 0.636 |       |       |
|                 | Coronary artery disease| 1.56 (1.09, 2.22) | 0.014 |       |       |
|                 | Chronic Renal Insufficiency | 2.81 (1.79, 4.43) | <0.001 |       |       |
| Model 4****     | NLR                    | 0.87 (0.12, 6.18) | 0.892 | 4.05 | 0.8526 |
|                 | FiO2                   | 1.01 (0.98, 1.05) | 0.246 |       |       |
|                 | Platelet count (×1000/cmm) | 0.997 (0.991, 1.00) | 0.460 |       |       |
|                 | INR                    | 0.31 (0.009, 10.11) | 0.516 |       |       |
|                 | Serum creatinine (mg/dl) | 1.11 (0.70, 1.75) | 0.648 |       |       |
|                 | Serum sodium (mEq/L)   | 1.02 (0.88, 1.18) | 0.732 |       |       |
|                 | PaCO2 mmHg             | 1.12 (0.96, 1.31) | 0.144 |       |       |
|                 | HCO3 mEq/L             | 0.96 (0.58, 1.59) | 0.885 |       |       |
|                 | PaO2 mmHg              | 0.91 (0.81, 1.03) | 0.173 |       |       |
|                 | Total bilirubin (mg/dl) | 1.35 (0.10, 17.8) | 0.816 |       |       |
|                 | Direct bilirubin (mg/dl) | 14.25 (0.37, 547.5) | 0.153 |       |       |
|                 | Serum albumin (g/dl)   | 2.11 (0.66, 6.72) | 0.205 |       |       |
|                 | ALT (U/L)              | 1.12 (ss)  | 0.033 |       |       |
|                 | AST (U/L)              | 1.13 (1.00, 1.28) | 0.036 |       |       |
|                 | CRP (mg/L)             | 0.98 (0.96, 1.00) | 0.122 |       |       |
|                 | ESR (first hour)       | 0.99 (0.98, 1.01) | 0.824 |       |       |
|                 | Serum ferritin (ng/ml) | 1.004 (1.0003, 1.008) | 0.031 |       |       |
|                 | D-dimer (microgm/ml)   | 0.998 (0.996, 1.0008) | 0.236 |       |       |

* Adjusted model to demographic variables.
** Adjusted model to Vital signs.
*** Adjusted model to Clinical characteristics.
**** Adjusted model to laboratory investigations.

https://doi.org/10.1371/journal.pone.0256203.t004
3.9. Gender disparity amongst the studied population

Male patients were more likely to be smokers (p < 0.001), had a history of close contact with positive cases (p = 0.043), being asymptomatic (p = 0.043), S1 Table.

4. Discussion

The landscape of the COVID-19 pandemic has changed over the past few months. The number of confirmed cases in the EMR rose sharply to more than 1,534,000 cases by the end of July 2020, with about 40,000 deaths reported, resulting in a 2.6% mortality rate [6]. Growing evidence shows that the different distributions of epidemiological characteristics between the affected countries may influence mortality rates. In addition, the clinical spectrum of COVID-19 disease appears to be broad, ranging from asymptomatic infection, mild upper respiratory tract disease, respiratory failure to severe viral pneumonia or death. The assessment of risk factors and predictors of the severity of the disease and the possibility of death is a very important issue for the prediction of the possible outcome.

In this study, we highlighted many risk factors that can be used as independent predictors for the severity of COVID-19. Age, especially patients older than 60 years, were significantly associated with worse outcomes of COVID-19. It has been observed that older age groups are more susceptible to infection and severe presentation, with higher mortality rates than younger patients, since the initial COVID-19 case clusters were reported [29]. While it was initially unclear whether the difference between age groups reflects the lower risk of severe disease or lower susceptibility to infection, recent reports demonstrated that the young population had similar susceptibility to older age groups; which, in return, highlights that the difference between age groups stems from the ability to fight the infection [30]. Several studies proposed many pathogenic mechanisms behind the critical illness in the elderly population, including low levels of angiotensin-converting enzyme 2 (ACE2) in the elderly [31], age-dependent difficulty in removing particles from small airways [32], excessive release of inflammatory mediators in elderly “inflammaging” [33], incompetent immune response, and high frequency of comorbidities in the elderly population [29]. Recent retrospective studies from Egypt [25], Iran [34], and Pakistan [35] demonstrated that older age groups were more susceptible to severe disease and death from COVID-19. This was in line with other reports from outside of EMR countries [36, 37].

Recent surveillance had shown that male patients were more susceptible to serious infection and mortality with COVID-19 [38], and this gender-specific difference had been observed in previous outbreaks of SARS [39]. In contrast, our study showed an insignificant difference between both genders in terms of COVID-19 severity. This observation was different from what was reported in the other reports from EMR countries [25, 34, 35]. This can be explained as we here investigate the risk of severity, not mortality. Similarly, Nasiri et al. showed that there was no significant difference between males and females in terms of ICU admissions [40]. Another Egyptian study of 260 patients with COVID-19 showed that there was no significant association between male gender and the risk of critical illness (OR = 1.84, 95% CI [0.80, 4.48], p = 0.156) [41]. In Italy, Ciceri et al. [42] reported that there was no significant association between female gender and risk of critical illness (OR = 1.09, 95% CI [0.69, 1.72], p = 0.70).

It is well documented that comorbidities in COVID-19 patients are major contributors to serious presentation and death. For example, poorly controlled diabetes was found to significantly increase the risk of composite adverse outcomes, including death, among COVID-19 cases [43]. Likewise, malignancies and chronic renal diseases were reported to be significant predictors of COVID-19 critical illness and mortality [44]. The preexistence of cardiovascular...
or chronic lung diseases worsens the outcomes of COVID-19 as well [45, 46]. In our study, diabetes mellitus, cardiovascular diseases, chronic renal disease, and cancer were significantly associated with a higher risk of critical illness. In a large cohort from China, hypertension, diabetes, and chronic obstructive pulmonary diseases were prevalent among severe COVID-19 cases [47]. Patients with preexistent comorbidities, such as diabetes and cardiovascular diseases, were more likely to suffer from the severe disease in another report of COVID-19 cases [48].

Low Oxygen saturation is one of the most important clinical features of COVID-19 patients. Our study showed that lower oxygen saturation was significantly associated with an increased risk of critical illness. In agreement, Petrilli et al. [36] showed that patients with deficient oxygen saturation (less than <88%) were associated with increased risk of critical COVID-19 (OR = 3.67, 95% CI [2.78, 4.8], p<0.001). Also, we found that patients with elevated temperature and increased pulsation were associated with an increased risk of critical illness. In contrast, Petrilli et al. could not find any significant association between elevated temperature and critical illness [36].

In our study, the critically ill patients showed significant leukocytosis. Similarly Zhao et al found that elderly patients with co-morbidities showed significant leukocytosis [49]. Patients with COVID-19 have a blood picture characterized by normal or low WBC count and decreased lymphocyte level [50]. Similarly, the elevation of CRP levels was observed in the majority of COVID-19 patients. Moreover, high levels of CRP and inflammatory biomarkers are considered one of the main characteristics of COVID-19 patients [51]. It was reported that early elevation of CRP has the strongest association with mechanical ventilation or mortality [52]. Furthermore, liver changes were one of the most common findings in the COVID-19 infected subjects. Liver injury may happen in COVID-19. It had been reported that that 14.8–53.1% of COVID-19 patients had elevated liver enzymes and bilirubin. Moreover, the degree of liver damage is proportional to the severity of COVID-19 [53, 54]. In patients with COVID-19, the serum level of ferritin was significantly elevated in critically ill patients. Similarly, it had been reported that serum level of ferritin increase with case deterioration and was significantly elevated in non-survivors compared with survivors [37]. Shoenfeld reported that the ferritin H-chain played a role in stimulating macrophages to increase inflammatory cytokine secretion. Thus, it became apparent to understand the pathogenesis of hyperferritinemia syndrome, including COVID-19 infection [55]. Our findings showed that ALT, AST, and serum ferritin could be used as a significant predictor for COVID-19 severity. Interestingly, our findings demonstrated that there was no significant association between the level of D-dimer and the severity of COVID-19. This finding was also observed by Ramadan et al. in another Egyptian study [41].

This article is one of the first reports about the predictors of COVID-19 severity in Egypt. However, we acknowledge that the present study had some limitations. First, data of the present study were collected retrospectively with some potential biases, such as case ascertainment bias and misclassification. Second, we might have overestimated the importance of chronic disease at risk of hospital admission due to the substantial heterogeneity among the included patients. Third, our patients were from a single geographical area, treated within a single health system; so factors correlated with poor outcomes might differ elsewhere. The lack of medical history at baseline was an additional limitation, recent reports highlighted that some medications, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), may facilitate severe infection [56]. Besides, a high frequency of obesity among patients admitted with severe COVID-19 [57]; however, there were no available data concerning obesity in the present study.
5. Conclusion
In conclusion, COVID-19 is a growing pandemic with an unprecedented spread rate and profound impact on the health of specific subsets of affected patients. In the present report, we demonstrated that many factors are associated with COVID-19 critical illness, including older age groups, fatigue, elevated temperature, increased pulse, lower oxygen saturation, the preexistence of diabetes, malignancies, cardiovascular disease, renal diseases, and pulmonary disease. Moreover, elevated serum levels of ALT, AST, and ferritin are associated with worse outcomes. Further studies are required to identify independent predictors of mortality for patients with COVID-19.

Supporting information
S1 Table. The difference in clinical and laboratory characteristics of the included patients according to gender.

(DOCX)

Author Contributions
Conceptualization: Dalia Omran, Hend Shousha, Muhammad Abdel Ghaffar.
Data curation: Mohamed Alsheikh, Enass El Sayed, Shimaa Afify, Samah Abdel Hafez, Khaled Elkelany, Ayman Eltayar, Omnia Ali, Lamiaa Kamal, Ahmed Heiba.
Formal analysis: Eshak Bahbah.
Methodology: Dalia Omran.
Supervision: Dalia Omran, Mohamed Al Soda, Muhammad Abdel Ghaffar.
Writing – original draft: Eshak Bahbah, Ahmed Elgebaly.
Writing – review & editing: Dalia Omran, Gamal Esmat, Muhammad Abdel Ghaffar.

References
1. (WHO) WHO. Rolling updates on coronavirus disease (COVID-19).
2. Mahalmani VM, Mahendru D, Semwal A, Kaur S, Kaur H, Sarma P, et al. COVID-19 pandemic: A review based on current evidence. Indian Journal of Pharmacology. Wolters Kluwer Medknow Publications; 2020. pp. 117–129. https://doi.org/10.4103/ip.JP_310_20 PMID: 3256599
3. World Health Organization. Weekly Operational Update on COVID-19 October 23, 2020. WHO. 2020. Available: https://www.who.int/publications/m/item/weekly-update-on-covid-19—23-october
4. Ahmed H, Sayed A, Munir M, Elberry MH, Sayed IM, Kamal MA, et al. A Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management. Curr Pharm Des. 2020; 26. https://doi.org/10.2174/138162826666202122162509 PMID: 33355050
5. Ebada MA, Allah AW, Bahbah E, Negida A, An Updated Review on COVID-19. Infect Disord Drug Targets. 2020. https://doi.org/10.2174/1871526520666201216165322 PMID: 33327924
6. World Health Organization (WHO). Coronavirus disease 2019 Situation Report 193. World Heal Organ. 2020. Available: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200731-covid-19-sitrep-193.pdf?sfvrsn=42a0221d_4
7. Ji W, Wang W, Zhao X, Zai J, Li X. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020; 92: 433–440. https://doi.org/10.1002/jmv.25682 PMID: 31967321
8. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environmental Research. 2020. https://doi.org/10.1016/j.envres.2020.109819 PMID: 32569870
9. Rothe C, Schunk M, Sothmann P, Bretzel G, Froschl G, Wallrauch C, et al. Transmission of 2019-NCoV infection from an asymptomatic contact in Germany. New England Journal of Medicine. 2020. pp. 970–971. https://doi.org/10.1056/NEJMc2001468 PMID: 32003551
10. Symptoms of Coronavirus | CDC.

11. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases. Elsevier B.V.; 2020. pp. 264–266. https://doi.org/10.1016/j.ijid.2020.01.009 PMID: 31953166

12. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7 PMID: 32077143

13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264

14. Coperchihi F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine and Growth Factor Reviews. Elsevier Ltd; 2020. pp. 25–32. https://doi.org/10.1016/j.cytogfr.2020.05.003 PMID: 32446778

15. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55. https://doi.org/10.1016/j.ijantimicag.2020.105954 PMID: 32234467

16. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 [cited 31 Mar 2020]. https://doi.org/10.1001/jamacardio.2020.1096 PMID: 32219357

17. Xie P, Ma W, Tang H, Liu D. Severe COVID-19: A Review of Recent Progress With a Look Toward the Future. Frontiers in Public Health. 2020. https://doi.org/10.3389/fpubh.2020.00189 PMID: 32574292

18. European Centre for Disease Prevention and Control. Situation update worldwide, as of 6 March 2020 08:00. 2020.

19. Lipsitch M, Donnelly CA, Fraser C, Blake IM, Cori A, Dorigatti I, et al. Potential biases in estimating absolute and relative case-fatality risks during outbreaks. PLoS Neglected Tropical Diseases. Public Library of Science; 2015. pp. 1–16. https://doi.org/10.1371/journal.pntd.0003846 PMID: 26181387

20. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 1–13. https://doi.org/10.1056/NEJMoa2002032 PMID: 32109013

21. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis; 2020: 3099: 1–9. https://doi.org/10.1016/S1473-3099(20)30243-7 PMID: 32240634

22. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020; 6: 4–7. https://doi.org/10.1038/s41421-019-0138-2 PMID: 32053334

23. Chen Y, Shan K, Qian W. Asians do not exhibit elevated expression or unique genetic polymorphisms for ACE2, the cell-entry receptor of SARS-CoV-2. 2020; 1–13. https://doi.org/10.20944/preprints202002.0258.v2

24. Egypt Cares. [cited 4 Nov 2020]. Available: https://www.care.gov.eg/EgyptCare/Index.aspx

25. Ghweil AA, Hassan MH, Mohamed AK, Mohamed AO, Mohammed HM, Abdelazeez AA, et al. Characteristics, Outcomes and Indicators of Severity for COVID-19 Among Sample of ESNA Quarantine Hospital’s Patients, Egypt: A Retrospective Study. Infect Drug Resist. 2020; 13: 2375–2383. https://doi.org/10.2147/IDR.S263489 PMID: 32765012

26. Ramadan HKA, Mahmoud MA, Zakaria M, Aburahma, Elkhawaga AA, El-Mokhtar MA, et al. Predictors of severity and co-infection resistance profile in COVID-19 patients: First report from upper Egypt. Infect Drug Resist. 2020; 13: 3409–3422. https://doi.org/10.2147/IDR.S272605 PMID: 33116660

27. Elm E Von Altman DG, Egger M Pocock SJ, Gøtzsche PC Vandenbro ucke JP, et al. The Strengtheni ng the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies*. Int J Surg. 2014; 12: 1495–1499. https://doi.org/10.1016/j.ijsu.2014.07.013 PMID: 25046131

28. Lin L, Li TS. Interpretation of “Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5).” Zhonghua Yi Xue Za Zhi. 2020; 100: E001. https://doi.org/10.3760/cma.j.issn.0376-2491.2020.0001 PMID: 32033513

29. Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D’Agnano V, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clinical and Experimental Research. Springer; 2020. p. 1. https://doi.org/10.1007/s40520-019-01392-3 PMID: 31721096
30. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts. medRxiv. 2020; 2020.03.03.20028423. https://doi.org/10.1101/2020.03.03.20028423

31. Alghatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights from Cardiovascular Aging Science. JAMA Cardiology. 2020. https://doi.org/10.1001/jamacardio.2020.1329 PMID: 32242886

32. Svatengren M, Falk R, Philipson K. Long-term clearance from small airways decreases with age. Eur Respir J. 2005; 26: 609–615. https://doi.org/10.1183/09031936.05.0002105 PMID: 16204590

33. Aw D, Silva AB, Palmer DB. Immunosenescence: Emerging challenges for an ageing population. Immunology. Wiley-Blackwell; 2007. pp. 435–446. https://doi.org/10.1111/j.1365-2567.2007.02555.x PMID: 17313487

34. Jalili M, Payandemehr P, Saghaei A, Sari HN, Safikhani H, Kolivand P. Characteristics and Mortality of Hospitalized Patients With COVID-19 in Iran: A National Retrospective Cohort Study. Ann Intern Med. 2020 [cited 4 Aug 2020]. https://doi.org/10.7326/M20-2911 PMID: 32687717

35. Chaudhry A, Ikram A, Baig MA, Salman M, Ghafoor T, Hussain Z, et al. Mortality Analysis of COVID-19 Confirmed cases in Pakistan. medRxiv. 2020; 2020.06.07.20121939. https://doi.org/10.1101/2020.06.07.20121939

36. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ. 2020; 369. https://doi.org/10.1136/bmj.m1966 PMID: 32444366

37. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171076

38. Aly MH, Rahman SS, Ahmed WA, Alghamdi MH, Al Shehri AA, Alkalkami AM, et al. Indicators of Critical Illness and Predictors of Mortality in COVID-19 Patients. Infect Drug Resist. 2020; Volume 13: 1995–2000. https://doi.org/10.2147/IDR.S261159 PMID: 32617010

39. Karlberg J, Chong DSY, Lai WYY. Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory Syndrome than Women Do? Am J Epidemiol. 2004; 159: 229–231. https://doi.org/10.1093/aje/kwh056 PMID: 14742282

40. Nasiri MJ, Haddadi S, Tahvildari A, Farsi Y, Arbabi M, Hasanzadeh S, et al. COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis. Frontiers in Medicine. 2020. https://doi.org/10.3389/fmed.2020.00459 PMID: 32793620

41. Ramadan HK-A, Mahmoud MA, Aburahma MZ, Elkhawaga AA, El-Mokhtar MA, Sayed IM, et al. Predictors of Severity and Co-Infection Resistance Profile in COVID-19 Patients: First Report from Upper Egypt. Infect Drug Resist. 2020; Volume 13: 3409–3422. https://doi.org/10.2147/IDR.S272605 PMID: 33116660

42. Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020; 217: 108509. https://doi.org/10.1016/j.clim.2020.108509 PMID: 32535188

43. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020. https://doi.org/10.1016/j.cmet.2020.04.021 PMID: 32369736

44. Sanyalou A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020; 1. https://doi.org/10.1007/s42399-020-00363-4 PMID: 32838147

45. Yahia F, Zakhama L, Ben Abdelaziz A. COVID-19 and cardiovascular diseases. Scoping review study. Tunisie Medicale. 2020. pp. 283–294. PMID: 32395790

46. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of Covid-19: A systematic review and meta-analysis. J Med Virol. 2020 [cited 4 Aug 2020]. https://doi.org/10.1002/jmv.25889 PMID: 32293753

47. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis. Eur Respir J. 2020; 55. https://doi.org/10.1183/13993003.00547–2020

48. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708–1720. https://doi.org/10.1056/NEJMoa2002322 PMID: 32109013

49. Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, et al. Clinical features in 82 patients with COVID-19 who have increased leukocyte count: a retrospective analysis. Eur J Clin Microbiol Infect Dis. 2020; 39: 2279–2287. https://doi.org/10.1007/s10096-020-03976-8 PMID: 32651736
50. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020. https://doi.org/10.1016/j.ijid.2020.03.053 PMID: 32251805

51. Wu Y, Potempa LA, El Kebir D, Filep JG. C-reactive protein and inflammation: Conformational changes affect function. Biological Chemistry. 2015. https://doi.org/10.1515/hsz-2015-0149 PMID: 26040008

52. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv. 2020. https://doi.org/10.1101/2020.04.08.20057794

53. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020; 35: 744–748. https://doi.org/10.1111/jgh.15047 PMID: 32215956

54. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003. https://doi.org/10.1016/s0140-6736(03)13077-2 PMID: 12711465

55. Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmunity Reviews. 2020. https://doi.org/10.1016/j.autrev.2020.102538 PMID: 32268212

56. Soria Arcos F, Romero Puche A, Vicente Vera T. Controversy regarding ACE inhibitors / ARBs in COVID-19. Rev Española Cardiol (English Ed. 2020; 73: 516. https://doi.org/10.1016/j.rec.2020.04.004 PMID: 32371022

57. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noullet J, Duhamel A, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity. 2020; 28: 1195–1199. https://doi.org/10.1002/oby.22831 PMID: 32271993